Stocksigma LogoStocksigma Logo

GSK Pharmaceuticals Reports Strong Q2 FY27 Financial and Operational Performance

GSK Pharmaceuticals delivered standalone Q2 FY27 revenue of ₹1,180cr (+21% YoY) and H1 revenue of ₹2,104cr (+18% YoY)

GSK Pharmaceuticals Reports Strong Q2 FY27 Financial and Operational Performance

GlaxoSmithKline Pharmaceuticals Ltd · Intimation · 04 Nov 2026, 6:38 pm

GSK Pharmaceuticals Reports Strong Q2 FY27 Financial and Operational Performance GSK Pharmaceuticals delivered standalone Q2 FY27 revenue of ₹1,180cr (+21% YoY) and H1 revenue of ₹2,104cr (+18% YoY). EBITDA grew 20% YoY to ₹400cr (34% margin, -50 bps YoY), while PAT surged 33% YoY to ₹335cr (29% margin), aided by income tax refund interest; Q2 EPS rose 32% to ₹19.76. Growth was driven by general medicines (Augmentin, Calpol) and doubled Shingrix sales, lifting the innovation portfolio to 7% of revenue versus 3% in prior year. GSK maintained 25% share in its represented market.

Original exchange filing (PDF)

More announcements from GlaxoSmithKline Pharmaceuticals Ltd

All GlaxoSmithKline Pharmaceuticals Ltd announcements